相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
Ibai Goicoechea et al.
BLOOD (2021)
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity
Benjamin T. Diamond et al.
BLOOD REVIEWS (2021)
The nuclear export protein XPO1-from biology to targeted therapy
Asfar S. Azmi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma
Gang An et al.
LEUKEMIA (2020)
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
Niccolo Bolli et al.
FRONTIERS IN ONCOLOGY (2020)
Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
Bastien Jamet et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
Rafael Alonso et al.
BLOOD ADVANCES (2020)
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Nikhil C. Munshi et al.
BLOOD ADVANCES (2020)
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
Elena Zamagni et al.
JOURNAL OF CLINICAL MEDICINE (2020)
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
Manman Deng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Emerging agents and regimens for multiple myeloma
Yang Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Alejandro Medina et al.
BLOOD CANCER JOURNAL (2020)
Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis
Hanqing Li et al.
ANNALS OF HEMATOLOGY (2019)
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy
Marcella A. Tschautscher et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions
Concetta Schiano et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse
Surbhi Sidana et al.
LEUKEMIA (2019)
Clinical and experimental evidence for targeting CD6 in immune-based disorders
Marta Consuegra-Fernandez et al.
AUTOIMMUNITY REVIEWS (2018)
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing
Guangwu Guo et al.
LEUKEMIA (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Longitudinal Flow Cytometry Identified Minimal Residual Disease (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma
Jingli Gu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot et al.
BLOOD (2018)
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
O. Landgren et al.
JOURNAL OF INTERNAL MEDICINE (2017)
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J. Flores-Montero et al.
LEUKEMIA (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2017)
The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic
Paolo Milani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics
Rajshekhar Chakraborty et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Better Therapy Requires Better Response Evaluation: Paving the Way for Minimal Residual Disease Testing for Every Myeloma Patient
Ola Landgren et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen
Ruth M. de Tute et al.
HAEMATOLOGICA (2016)
Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?
C. Pawlyn et al.
LEUKEMIA (2016)
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen
Ruth M. de Tute et al.
HAEMATOLOGICA (2016)
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
Bruno Paiva et al.
BLOOD (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Minimal residual disease in multiple myeloma: bringing the bench to the bedside
Sham Mailankody et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde et al.
JAMA ONCOLOGY (2015)
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
Bruno Paiva et al.
HAEMATOLOGICA (2015)
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
T. Paino et al.
LEUKEMIA (2015)
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Joaquin Martinez-Lopez et al.
BLOOD (2014)
Curing myeloma at last: defining criteria and providing the evidence
Bart Barlogie et al.
BLOOD (2014)
Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal Gammopathy
David R. Barnidge et al.
JOURNAL OF PROTEOME RESEARCH (2014)
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
N. Puig et al.
LEUKEMIA (2014)
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
M. Ladetto et al.
LEUKEMIA (2014)
Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
A. C. Logan et al.
LEUKEMIA (2013)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
Malek Faham et al.
BLOOD (2012)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment
Aaron C. Logan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Histology and immunohistology of bone marrow biopsy in multiple myeloma
S. Pileri et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients
Bruno Paiva et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Measurement and Clinical Monitoring of Human Lymphocyte Clonality by Massively Parallel V-D-J Pyrosequencing
Scott D. Boyd et al.
SCIENCE TRANSLATIONAL MEDICINE (2009)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
Peter J. Campbell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
V. H. J. van der Velden et al.
LEUKEMIA (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma
MHC Bakkus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation
AC Rawstron et al.
BLOOD (2002)
分享论文
